Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2/3, Multi-center, Two-part Clinical Trial to Evaluate the Safety and Efficacy of Gene Therapy for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation

NCT04912843 is registered in ClinicalTrials.gov with Wuhan Neurophth Biotechnology Limited Company as lead sponsor.

NCT NCT04912843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04912843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2/3, Multi-center, Two-part Clinical Trial to Evaluate the Safety and Efficacy of Gene Therapy for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
Lead sponsor
Wuhan Neurophth Biotechnology Limited Company
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 18, 2021
Completion date
February 29, 2028
Enrollment
102 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leber's hereditary optic neuropathy (lhon)